Home/Pipeline/Avoralstat

Avoralstat

Diabetic Macular Edema (DME)

Phase 2Investigational (Non-Core)

Key Facts

Indication

Diabetic Macular Edema (DME)

Phase

Phase 2

Status

Investigational (Non-Core)

Company

BioCryst Pharmaceuticals

About BioCryst Pharmaceuticals

Founded in 1986, BioCryst Pharmaceuticals is a global, commercial-stage biotech company headquartered in Durham, North Carolina, focused on discovering and developing novel treatments for rare diseases. Its core expertise lies in structure-guided drug design, which it uses to create highly selective oral and injectable therapies. The company has successfully commercialized ORLADEYO for HAE and is advancing a pipeline of investigational candidates, including navenibart for HAE and BCX17725 for Netherton syndrome, while also marketing RAPIVAB for influenza.

View full company profile

Therapeutic Areas

Rare Diseases Hereditary Angioedema Complement-Mediated Diseases Dermatology Infectious Diseases

Other Diabetic Macular Edema (DME) Drugs

Drug	Company	Phase	Status
OCS-01	Oculis Holding AG	Phase 3	Active
Tarcocimab Tedromer (KSI-301)	Kodiak Sciences	Phase 3	GLEAM & GLIMMER Studies Complete
DURAVYU™ (EYP-1901)	EyePoint Pharmaceuticals	Phase 3	Active - Pivotal COMO & CAPRI trials underway
Sozinibercept (OPT-302)	Opthea	Phase 3	Active
4D-150	4D Molecular Therapeutics	Phase 3	Active - Phase 3 planned following RMAT designation
ONS-5010 / LYTENAVA™ (bevacizumab-vikg)	Outlook Therapeutics	Phase 3	Planned development
UBX1325 (foselutoclax)	Unity Biotechnology	Phase 2b	Active